The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials
Conclusion: Gefitinib might be more efficient than chemotherapy, but less efficient than other targeted therapies in ORR, especially in EGFR mutation-positive patients. Gefitinib can decrease the odds of hematologic toxicity compared to controls. Future studies, especially those with EGFR mutation-positive patients, will be needed to confirm our findings.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Hongmei Wo, Jing He, Yang Zhao, Hao Yu, Feng Chen, Honggang Yi Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Skin | Study | Toxicology